Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer
Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these pr...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ANDERSEN LARS DYRSKJOT NOVORADOVSKY ALEXEY ORNTOFT TORBEN FALCK SORGE JOSEPH A |
| description | Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2013122504A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2013122504A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2013122504A13</originalsourceid><addsrcrecordid>eNqNjLsKwkAQANNYiPoPC9aBvPyA5IhYRA2odVhymwcet3HvUD9fCy3srAaGYebBrXxOQs6NbKGiOxkH3IE6VlmeFjWg1cB-IIE9ypXEgWIRMuhH28Nj9APUwv33wAIHtuGP6qAwqPV7odC2JMtg1qFxtPpwEay35VntQpq4ITdhS5Z8czklUZzGSbKJsjxO_6tewPJDGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer</title><source>esp@cenet</source><creator>ANDERSEN LARS DYRSKJOT ; NOVORADOVSKY ALEXEY ; ORNTOFT TORBEN FALCK ; SORGE JOSEPH A</creator><creatorcontrib>ANDERSEN LARS DYRSKJOT ; NOVORADOVSKY ALEXEY ; ORNTOFT TORBEN FALCK ; SORGE JOSEPH A</creatorcontrib><description>Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130516&DB=EPODOC&CC=US&NR=2013122504A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130516&DB=EPODOC&CC=US&NR=2013122504A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ANDERSEN LARS DYRSKJOT</creatorcontrib><creatorcontrib>NOVORADOVSKY ALEXEY</creatorcontrib><creatorcontrib>ORNTOFT TORBEN FALCK</creatorcontrib><creatorcontrib>SORGE JOSEPH A</creatorcontrib><title>Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer</title><description>Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLsKwkAQANNYiPoPC9aBvPyA5IhYRA2odVhymwcet3HvUD9fCy3srAaGYebBrXxOQs6NbKGiOxkH3IE6VlmeFjWg1cB-IIE9ypXEgWIRMuhH28Nj9APUwv33wAIHtuGP6qAwqPV7odC2JMtg1qFxtPpwEay35VntQpq4ITdhS5Z8czklUZzGSbKJsjxO_6tewPJDGg</recordid><startdate>20130516</startdate><enddate>20130516</enddate><creator>ANDERSEN LARS DYRSKJOT</creator><creator>NOVORADOVSKY ALEXEY</creator><creator>ORNTOFT TORBEN FALCK</creator><creator>SORGE JOSEPH A</creator><scope>EVB</scope></search><sort><creationdate>20130516</creationdate><title>Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer</title><author>ANDERSEN LARS DYRSKJOT ; NOVORADOVSKY ALEXEY ; ORNTOFT TORBEN FALCK ; SORGE JOSEPH A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2013122504A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2013</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>ANDERSEN LARS DYRSKJOT</creatorcontrib><creatorcontrib>NOVORADOVSKY ALEXEY</creatorcontrib><creatorcontrib>ORNTOFT TORBEN FALCK</creatorcontrib><creatorcontrib>SORGE JOSEPH A</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ANDERSEN LARS DYRSKJOT</au><au>NOVORADOVSKY ALEXEY</au><au>ORNTOFT TORBEN FALCK</au><au>SORGE JOSEPH A</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer</title><date>2013-05-16</date><risdate>2013</risdate><abstract>Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2013122504A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A36%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ANDERSEN%20LARS%20DYRSKJOT&rft.date=2013-05-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2013122504A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |